The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan

Abstract This study aims to investigate the prevalence of short-acting β2-agonist (SABA) overuse in asthma and the associated risk of acute exacerbation and mortality in Taiwan. We used the Taiwanese pay-for-performance asthma program database, which included patients aged between 12 and 100 years w...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cheng-Yi Wang, Chih-Cheng Lai, Ya-Hui Wang, Hao-Chien Wang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Diseases of the respiratory system RC705-779
Acceso en línea:	https://doaj.org/article/7d916fe16ae146a6a723749a03fcd30e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7d916fe16ae146a6a723749a03fcd30e
record_format	dspace
spelling	oai:doaj.org-article:7d916fe16ae146a6a723749a03fcd30e2021-12-02T18:27:45ZThe prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan10.1038/s41533-021-00231-12055-1010https://doaj.org/article/7d916fe16ae146a6a723749a03fcd30e2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41533-021-00231-1https://doaj.org/toc/2055-1010Abstract This study aims to investigate the prevalence of short-acting β2-agonist (SABA) overuse in asthma and the associated risk of acute exacerbation and mortality in Taiwan. We used the Taiwanese pay-for-performance asthma program database, which included patients aged between 12 and 100 years who were enrolled in the program between 2001 and 2015. Among a total of 218,039 patients, 34,641 (15.9%) patients are classified as SABA over-users. Compared with patients who did not receive inhaled corticosteroids (ICS) and collected ≤2 canisters, SABA over-users had a higher risk of severe exacerbations. SABA over-users had a higher risk of all-cause mortality compared with patients who did not receive ICS and collected ≤2 canisters. The overall prevalence of SABA overuse in Taiwan is 15.9%, and this is even higher in concomitant ICS users. In addition, the overuse of SABA is associated with an increased risk of severe exacerbation and death.Cheng-Yi WangChih-Cheng LaiYa-Hui WangHao-Chien WangNature PortfolioarticleDiseases of the respiratory systemRC705-779ENnpj Primary Care Respiratory Medicine, Vol 31, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the respiratory system RC705-779
spellingShingle	Diseases of the respiratory system RC705-779 Cheng-Yi Wang Chih-Cheng Lai Ya-Hui Wang Hao-Chien Wang The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan
description	Abstract This study aims to investigate the prevalence of short-acting β2-agonist (SABA) overuse in asthma and the associated risk of acute exacerbation and mortality in Taiwan. We used the Taiwanese pay-for-performance asthma program database, which included patients aged between 12 and 100 years who were enrolled in the program between 2001 and 2015. Among a total of 218,039 patients, 34,641 (15.9%) patients are classified as SABA over-users. Compared with patients who did not receive inhaled corticosteroids (ICS) and collected ≤2 canisters, SABA over-users had a higher risk of severe exacerbations. SABA over-users had a higher risk of all-cause mortality compared with patients who did not receive ICS and collected ≤2 canisters. The overall prevalence of SABA overuse in Taiwan is 15.9%, and this is even higher in concomitant ICS users. In addition, the overuse of SABA is associated with an increased risk of severe exacerbation and death.
format	article
author	Cheng-Yi Wang Chih-Cheng Lai Ya-Hui Wang Hao-Chien Wang
author_facet	Cheng-Yi Wang Chih-Cheng Lai Ya-Hui Wang Hao-Chien Wang
author_sort	Cheng-Yi Wang
title	The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan
title_short	The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan
title_full	The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan
title_fullStr	The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan
title_full_unstemmed	The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan
title_sort	prevalence and outcome of short-acting β2-agonists overuse in asthma patients in taiwan
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/7d916fe16ae146a6a723749a03fcd30e
work_keys_str_mv	AT chengyiwang theprevalenceandoutcomeofshortactingb2agonistsoveruseinasthmapatientsintaiwan AT chihchenglai theprevalenceandoutcomeofshortactingb2agonistsoveruseinasthmapatientsintaiwan AT yahuiwang theprevalenceandoutcomeofshortactingb2agonistsoveruseinasthmapatientsintaiwan AT haochienwang theprevalenceandoutcomeofshortactingb2agonistsoveruseinasthmapatientsintaiwan AT chengyiwang prevalenceandoutcomeofshortactingb2agonistsoveruseinasthmapatientsintaiwan AT chihchenglai prevalenceandoutcomeofshortactingb2agonistsoveruseinasthmapatientsintaiwan AT yahuiwang prevalenceandoutcomeofshortactingb2agonistsoveruseinasthmapatientsintaiwan AT haochienwang prevalenceandoutcomeofshortactingb2agonistsoveruseinasthmapatientsintaiwan
_version_	1718378046989271040

The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan

Ejemplares similares